More information: Call 0330 159 8162 or e-mail us
Take a couple of minutes to see how revaluing defined benefit pension schemes can significantly improve company finances.

In the past, we’d found it difficult to reconcile some of the mortality assumptions used in the calculation of our liabilities with the actual experience in our pensioner population. We felt a medically underwritten approach, in which scheme members were actually asked for the facts about their health, would help us better determine our pensioner liabilities and, all-importantly, the funding needs of the scheme.

Ashley Wilton, chair of the JT Dove pension scheme trustees

Accurate, evidence-based valuations

MorganAsh evaluates pension schemes, using evidence-based underwriting – which delivers far more accurate funding valuations.

JT Dove

Builders merchant JT Dove reduced its forecast pension deficit by 11% after commissioning medical underwriters MorganAsh to re-examine mortality calculations.

BSW Timber

Following studies by MorganAsh, BSW Timber & Howie Forest Products received a good reduction from the insurers which enabled them to pursue a buy-in transaction, thus de-risking the schemes.

CML Microsystems

A medically underwritten mortality study reduced the deficit in the scheme by around 10% – and enabled scheme members to better evaluate their options of remaining in the scheme or transferring out.

More information: Call 0330 159 8162 or e-mail us
Medically underwritten mortality studies

Medically underwritten mortality studies

The need

Pension scheme sponsors and trustees must assess the value of their defined benefit pension schemes for accounting, ongoing funding purposes and regulatory purposes. As part of this, assumptions have to be made about the mortality of scheme members. Most traditional methods of assessing mortality are fundamentally flawed. They rely on the assumptions of standard tables, and analysis of often obsolescent postcode data, rather than solid information – and can therefore vary wildly. The resulting business impact can be significant, risking overstated accounting disclosures and unnecessarily high contribution levels; for trustees, investment strategies and buy-out plans can be materially different.

The service

MorganAsh provides an alternative approach to setting mortality assumptions for scheme valuations which can deliver a different perspective. We assess the health of individual scheme members and then work with actuaries and trustees to formulate a more appropriate mortality assumption for pension schemes, using long-established life-insurance, medical-underwriting techniques. This evidence-based approach has typically shown variations of 5–10% in valuations, resulting in changes in valuations of millions of pounds.


  • Telephone surveys are undertaken by our qualified nurses, who are highly experienced in working with consumers.
  • We provide a well-defined, structured, proven service.
  • We provide you with an evidence-based approach to setting mortality assumptions, which is based on real data from the actual scheme membership.


  • We provide evidence-based, improved-accuracy, scheme-funding and accounting valuations.
  • Meets The Pension Regulator’s requirements for an evidence-based methodology.
  • We can help resolve differences of opinion between scheme sponsors and trustees during valuation assumption negotiations.
  • We can help companies to prepare for future buy-in/-out transactions.
  • Using medically underwritten mortality studies improves risk management.
  • We can help facilitate mergers and acquisitions activity.

Gathering scheme data

Scheme data is sensitively gathered by a team of medical professionals, working with secure information systems which have been developed specifically for the purpose by MorganAsh. How we gather scheme data.



Find out more

Medically underwritten mortality studies are suitable for all final-salary pension schemes – particularly those with under 1,000 members, where the population is too small and unlikely to be represented by standard national averages.


Whether in the process of agreeing a pension scheme valuation or not, medically underwritten mortality studies could help to improve the accuracy of results.


E-mail us at, or call us – and we will be happy to chat.


If you would like to find out more why not join us for a free webinar. Click here to register.

Related services

Our work with clients

Medically underwritten mortality studies

If you are interested in medically underwritten mortality studies, please get in touch. We’ll be happy to help.


Our clients say:

The FCA requires advisers and providers to understand their customers in far more detail – to better anticipate and avoid foreseeable harms. We need good tech to help us do this. The MorganAsh MARS tool – with its objective ‘resilience rating’ – is a great step to making this transition easier.

Johnny Timpson OBE, Financial Inclusion Commissioner